Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sevelamer hydrochlorid, ATC V03AE02 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. V.-Option 1x12 Monate)
Description
Section 130a, paragraph 8, of the German Social Code (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-specific, formal tendering procedures is carried out by DAK-Gesundheit in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the above-mentioned active substance Sevelamer hydrochloride, ATC V03AE02, DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the authorisation model for the above-mentioned active substance will come into force for the first time on 01.01.2027 and will end on 31.12.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, irrespective of this.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Glycopyrronium + Indacaterol, ATC R03AL12 für die Zeit 01.01.2027 - 31.12.2028
DAK-GesundheitGermanyPharmaceutical productsDeadline in 719 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mometason (ausschl. in der Dafo. Lösung), ATC D07AC13 f. d. Z. 01.01.2027-31.12.2028 (zzgl. V.-Option 1x12 M)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pamidronsäure, ATC M05BA03 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. V.-Option 1x12 Monate)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Morphin (ausschl. in der Dafo. FTA + HKP + SMT), ATC N02AA01 f. d. Z. 01.01.27-31.12.28, zzgl V.-Option 1x12M
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026